00000nam 2200000za 4500 9.856559 CaOODSP 20221107155547 cr ||||||||||| 180514s2018 onc #ob f000 0 eng d 978-0-660-26580-3 CaOODSP eng n-cn--- H164-236/2018E-PDF Submission of targeted risk management plans and follow-up commitments for prescription opioid-containing products [electronic resource] : guidance for industry. Guidance for industry Ottawa : Health Canada, 2018. iii, 23 p. "Effective date May 2, 2018." Title from cover. "Your health and safety ... our priority." Issued also in French under title: Présentation des plans de gestion des risques ciblés et des engagements de suivi pour les produits sur ordonnance à base d’opioïdes : document d’orientation à l’intention de l’industrie. Includes bibliographical references. "Opioids are regulated under the Food and Drugs Act and the Controlled Drugs and Substances Act. A majority of the marketed prescription opioid products are used to treat pain, but some are also used to control moderate to severe cough, to control diarrhea, as anesthetics, and to treat opioid use disorder"--Introduction, p. 1. gccst Prescription drugs gccst Risk management gccst Industrial policy Canada. Health Canada. Présentation des plans de gestion des risques ciblés et des engagements de suivi pour les produits sur ordonnance à base d’opioïdes (CaOODSP)9.856560 PDF 836 KB https://publications.gc.ca/collections/collection_2018/sc-hc/H164-236-2018-eng.pdf Pub.: 180050